Nuvectis Pharma (NVCT) Non-Current Assets (2021)
Nuvectis Pharma (NVCT) posted Non-Current Assets of $824000.0 for Q4 2021.
Powered by 
Analysis
Nuvectis Pharma (NVCT) Non-Current Assets (2021) Analysis & Trends
Nuvectis Pharma has reported Non-Current Assets for 1 years, with the latest figure at $824000.0 in Q4 2021.
- Quarterly Non-Current Assets changed N/A year-over-year to $824000.0 in Q4 2021, while the trailing twelve-month figure through Sep 2022 was $824000.0 (changed N/A YoY) and the FY2021 annual result came in at $824000.0, changed N/A from the prior year.
- Non-Current Assets held at $824000.0 in Q4 2021 per NVCT's latest filing.
- Over five years, Non-Current Assets peaked at $824000.0 in Q4 2021 and troughed at $824000.0 in Q4 2021.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 5.15 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 294.93 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 1.96 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 938.60 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 18.06 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Nuvectis Pharma | 573.99 Mn | 573.99 Mn | - | - |